What are other abortive medications for migraine (migraine headaches)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Abortive medications for migraine, such as gepants (e.g., ubrogepant and rimegepant) and ditans (e.g., lasmiditan), are effective alternatives to triptans, with a "weak for" recommendation for ubrogepant and rimegepant, and a "neither for nor against" recommendation for lasmiditan 1. When considering abortive therapies for migraine, the goals include rapid and sustained alleviation of pain and restoration of function.

  • Gepants, such as ubrogepant (Ubrelvy, 50-100mg) and rimegepant (Nurtec ODT, 75mg), work by blocking CGRP receptors and can be taken at the onset of migraine with repeat dosing as needed per prescription.
  • Ditans, like lasmiditan (Reyvow, 50-200mg), target 5-HT1F receptors and are particularly useful for patients with cardiovascular contraindications to triptans.
  • For mild to moderate migraines, NSAIDs such as ibuprofen (400-800mg), naproxen sodium (500-550mg), or aspirin (900-1000mg) can be effective when taken early, with aspirin–acetaminophen–caffeine having a "strong for" recommendation 1.
  • Combination medications like acetaminophen/aspirin/caffeine (Excedrin Migraine) work through multiple mechanisms to relieve pain.
  • Antiemetics including metoclopramide (10mg), prochlorperazine (10mg), or chlorpromazine can address both nausea and migraine pain.
  • Neuromodulation devices provide non-medication options, although the evidence for their use is limited 1. These alternatives are particularly valuable for patients who don't respond to triptans, have contraindications, or experience unacceptable side effects.
  • For optimal results, abortive medications should be taken at the earliest signs of migraine, and patients should limit use to 2-3 days per week to prevent medication overuse headaches.
  • Greater occipital nerve blockade received a "weak for" recommendation for the abortive treatment of migraine, with balanced risks and benefits 1.

From the FDA Drug Label

Other Drug-Drug Interaction Evaluations: No significant pharmacokinetic interactions were observed for either ubrogepant or co-administered drugs when UBRELVY was administered with ... sumatriptan,

  • Other abortive medications for migraine include:
    • Sumatriptan
    • Atogepant
    • Erenumab
    • Galcanezumab 2

From the Research

Abortive Medications for Migraine

Other abortive medications for migraine include:

  • Lasmiditan, which is the first in its class approved for acute migraine treatment and exerts its therapeutic effect through agonism at the 5-HT1F receptor without inducing vasoconstriction 3
  • Ubrogepant, a selective CGRP antagonist that has been evaluated in large short- and long-term Phase 2 and 3 clinical trials for clinical efficacy and safety as an acute migraine medication 4, 5
  • Triptans, such as eletriptan, sumatriptan, almotriptan, naratriptan, frovatriptan, rizatriptan, and zolmitriptan, which are serotonin 5-HT1B/1D receptor agonists that effectively relieve the pain, disability, and associated symptoms of migraine 6
  • Rimegepant and Nurtec, which are also CGRP receptor antagonists mentioned in the study of lasmiditan 3

Mechanism of Action

These medications work through different mechanisms, including:

  • Agonism at the 5-HT1F receptor (lasmiditan) 3
  • Antagonism of the CGRP receptor (ubrogepant, rimegepant, and Nurtec) 3, 4, 5
  • Agonism at the serotonin 5-HT1B/1D receptor (triptans) 6

Clinical Use

These medications are used for the acute treatment of migraine attacks, and the choice of medication depends on various factors, including the patient's medical history, presence of comorbidities, and previous response to treatment 3, 4, 6, 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Lasmiditan: Acute Migraine Treatment Without Vasoconstriction. A Review.

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians, 2021

Research

Ubrogepant for the treatment of migraine.

Expert opinion on pharmacotherapy, 2020

Research

Treating acute migraine with ubrogepant.

JAAPA : official journal of the American Academy of Physician Assistants, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.